BridgeBio Pharma Inc
For the period ended Mar 31, 2025. Filed Apr 29, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed Apr 29, 2025
BBIO$74.29+0.0%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| BridgeBio Pharma, Inc. | ||
| Date: April 29, 2025 | By: | /s/ Neil Kumar |
|---|---|---|
| Neil Kumar, Ph.D. | ||
| Chief Executive Officer, Director | ||
| (Principal Executive Officer) | ||
| Date: April 29, 2025 | By: | /s/ Thomas Trimarchi |
| Thomas Trimarchi, Ph.D. | ||
| President and Chief Financial Officer | ||
| (Principal Financial Officer) | ||
| Date: April 29, 2025 | By: | /s/ Maricel M. Apuli |
| Maricel M. Apuli | ||
| Chief Accounting Officer | ||
| (Principal Accounting Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.